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Here, we wish to highlight the genetic exchange and epigenetic interactions between
Epstein–Barr virus (EBV) and its host. EBV is associated with diverse lymphoid and
epithelial malignancies. Their molecular pathogenesis is accompanied by epigenetic
alterations which are distinct for each of them. While lymphoblastoid cell lines derived
from B cells transformed by EBV in vitro are characterized by a massive demethylation
and euchromatinization of the viral and cellular genomes, the primarily malignant lymphoid
tumor Burkitt’s lymphoma and the epithelial tumors nasopharyngeal carcinoma and EBV-
associated gastric carcinoma are characterized by hypermethylation of a multitude of
cellular tumor suppressor gene loci and of the viral genomes. In some cases, the viral
latency and oncoproteins including the latent membrane proteins LMP1 and LMP2A and
several nuclear antigens affect the level of cellular DNA methyltransferases or interact with
the histone modifying machinery. Specific molecular mechanisms of the epigenetic dialog
between virus and host cell remain to be elucidated.
Keywords: chromatin, CpG island, epigenome, viral latency, lytic cycle, pioneer transcription factor, tumor
suppressor gene, tumor virus
EPSTEIN–BARR VIRUS—THE FIRST HUMAN TUMOR VIRUS
Epstein–Barr virus (EBV), the proto-typical gamma-herpesvirus
infecting humans, has been discovered 50 years ago in cultured
Burkitt’s lymphoma (BL) cells (Epstein et al., 1964). EBV physio-
logically homes to memory B cells, a property which is reflected
in the genus name Lymphocryptovirus for gamma-herpesviruses
which “hide in lymphoid cells.” EBV is the causative agent of
infectious mononucleosis, and was the first known human tumor
virus. In addition to BL, an endemic childhood tumor mainly of
equatorial Africa, EBV plays a role in the origin or progression
of other primarily malignant B cell tumors, such as Hodgkin
lymphoma, and diverse AIDS-associated lymphomas including
lymphomas of the central nervous system. A profound failure of
T cell surveillance may allow early-onset post-transplant lympho-
proliferative disorder (PTLD) which may be overcome upon a
timely onset of T cell control, but may turn malignant if growing
uncontrolled for too long a time span.
In the first decade of EBV research, EBV was considered a
purely lymphotropic virus. Finding viral DNA in cellular DNA
from biopsies of anaplastic carcinomas of the nasopharynx (NPC,
nasopharyngeal carcinoma) by DNA hybridization did not change
that general view, because NPC as a lymphoepithelial tumor
contains a great many of infiltrating lymphocytes (zur Hausen
et al., 1970). Localizing the virus specifically to the malignant
epithelial cells first established EBV infection of non-lymphatic
cells and paved the way for the novel concept of EBV as an
epithelial tumor virus (Wolf et al., 1973). NPC is an endemic
tumor with a strong preference for South East Asia, especially
Guangdong and Hong Kong, with an incidence rate of 20–
30 cases per 100,000 persons per year, and virtually 100% of
non-keratinizing and undifferentiated NPCs are EBV-associated.
Almost two decades later on, the association of EBV with gastric
carcinomas (EBVaGC) was established, too (Burke et al., 1990;
Shibata et al., 1991). Contrary to the endemic tumor NPC, about
10% of the worldwide sporadic tumor gastric carcinoma (GC)
are associated with EBV infection. Among gastric remnant car-
cinomas approximately 30% and among lymphoepithelioma-like
GCs, approximately 80% are EBV-associated. Altogether, EBVaGC
with an estimated more than 80,000 cases per year is probably the
most frequent EBV-associated malignancy worldwide (reviewed
in Niller et al., 2014a,b). Beyond the B cell lineage, EBV infection
is currently associated with T cell lymphomas, epithelial tumors,
and rarely with leiomyosarcoma, a neoplasm of mesodermal ori-
gin (McClain et al., 1995). Furthermore, the risk of autoimmune
disease, including multiple sclerosis, is significantly increased after
primary EBV-infection, and even more so after symptomatic
primary infection, i.e., mononucleosis (Niller et al., 2008).
PATHOGENESIS OF EBV-ASSOCIATED TUMORS
The spectacular ability of EBV to transform and immortalize B
cells dominated the first four decades of EBV research and tumor
virology. General view was that the EBV-transformed cell was
the origin of the endemic BL cell, too, although a fundamental
difference of the epidemiology and pathogenesis between lym-
phoblastoid cell line (LCL)-like tumors on one side (early onset
PTLD), and of primarily malignant EBV-associated lymphomas
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Table 1 | Host cell-dependent expression of latent Epstein–Barr virus
proteins.
Protein Cell type and latency type
BL NPC CLL LCL
Type I Type IIa Type IIb Type III
EBNA1 + + + +
EBNA2 − − + +
LMP1 − +/− − +
LMP2A − + + +
BARF1 − + − −
Key viral latency proteins or so-called oncoproteins are differentially expressed
in EBV-associated malignancies and transformed cell lines. Depending on the
specific viral gene expression patterns, specific viral latency classes are defined.
BL, Burkitt’s lymphoma; NPC, nasopharyngeal carcinoma; CLL, chronic lympho-
cytic leukemia; LCL, lymphoblastoid cell line; EBNA, Epstein–Barr virus nuclear
antigen; LMP, latent membrane protein; BARF1, BamHI A rightward frame 1.
on the other side (endemic BL) became evident. Early onset PTLD
originate under conditions of severe immune suppression and
depend on viral transforming functions, including EBV nuclear
antigens (EBNAs) and latent membrane proteins (LMPs) that
are expressed both in PTLDs in vivo and in LCLs immortal-
ized in vitro. On the other hand, BL and Hodgkin lymphoma
originate under conditions of hyperstimulation of the lymphoid
germinal center reaction, and they do not depend on EBNA2
which the vast majority of them do not express (Klein, 1987;
Lenoir and Bornkamm, 1987; Table 1). In this context, it is
important to distinguish between morphological and oncogenic
transformation (Niller et al., 2011). Our discovery of a bind-
ing site for the oncoprotein c-Myc in the central locus control
region of the EBV genome suggested that the molecular patho-
genesis of endemic BL does not depend on a previous EBNA2-
transformed state of the B cell, but mostly on a dysbalance
of pro- and anti-apoptotic functions in consequence of Myc-
translocation, a molecular accident in a virus-infected B cell
undergoing the germinal center reaction (Niller et al., 2003). The
need to counter-balance the pro-apoptotic force of translocated
c-Myc through anti-apoptotic functions, either encoded by the
viral genome or induced by virus infection, in order for a BL
to emerge has recently been re-emphasized (Mbulaiteye, 2013;
Westhoff Smith and Sugden, 2013; Rickinson, 2014). Our dif-
ferential pathogenesis model for EBV-associated lymphomas was
controversial at first (Rossi and Bonetti, 2004; Thorley-Lawson,
2004; reviewed in Niller et al., 2012), but has now gained strong
support by recent large-scale epigenomic analyses of LCLs and
tumor cells (see below). Thus, finding the binding site for the
oncoprotein c-Myc in the locus control region of EBV caused
a conceptual shift away from the morphologically transformed
cell and has turned out as a heuristic discovery (Niller et al.,
2003).
GENETIC EXCHANGE BETWEEN HERPESVIRUSES AND HOST
CELLS
Homology between herpesviral and human genes is now a com-
mon theme which was first highlighted by the finding of a gene
for a functional thymidylate synthase (TS) in the genome of her-
pesvirus saimiri with an extremely high homology of 70% iden-
tical amino acids with the human TS gene. Various parameters
suggested that the TS gene had been acquired in virus evolution
by an ancestral herpesvirus from the cellular genome (Bodemer
et al., 1986; Honess et al., 1986). The exchange of human and
viral genes, and in the case of human herpesvirus 6 (HHV-6)
the invasion of an entire herpesviral genome into the human
germ line (Daibata et al., 1999) in about 0.8% of humans, must
have happened on numerous occasions in evolutionary time.
In the case of EBV, the intimate evolutionary relationship of
virus and host cell is emphasized by the presence of several viral
genes with sequence homology to cellular genes, i.e., BHRF1
and BALF1, two anti-apoptotic BCL2 homologs, BILF1, coding
for a constitutively active G protein-coupled receptor (GPCR)
homolog, and BCRF1, an IL-10 (interleukin 10) gene homolog.
The BCRF1 protein appears to be a functional homolog of IL-
10, an immune suppressive cytokine secreted by Th2 cells with a
sequence identity of about 70% (Hsu et al., 1990). The sequence
homologies of the other three viral peptides are of lower degree
than that. BHRF1 carries a 25% identity of a 150 amino acid C-
terminal portion with the anti-apoptotic cellular protein BCL2
(Cleary et al., 1986). BALF1 shows homology at a similar degree
in functionally important domains to its cellular counterparts
BCL2 and BCLX (Marshall et al., 1999). BILF1 carries a homology
of around 20% with the human chemokine receptor CXCR3A
(Davis-Poynter and Farrell, 1996; Beisser et al., 2005; Paulsen
et al., 2005). EBV-associated carcinoma cells express BARF1,
identified initially as a lytic cycle protein that binds to hCSF-1
(human colony stimulating factor 1) as a viral decoy receptor,
although its crystal structure is most closely related to CD80, a
co-stimulatory molecule of antigen presenting cells (Seto et al.,
2005; Tarbouriech et al., 2006; Elegheert et al., 2012).
Herpesviral DNA-binding proteins ICP8 of HSV1 and BALF2
of EBV, and additional homologous proteins of human her-
pesviruses which are required for viral replication belong to a
class of “DDE/RNase H-like fold-family” nucleases, together with
the recombination activating gene (RAG) 1 protein, essential for
V(D)J recombination, and the Argonaute protein of the RNA-
induced silencing complex (RISC). For ICP8 of HSV, divalent
cation binding of the DDE-site was actually shown to be func-
tional and required for viral replication (Bryant et al., 2012).
Furthermore, inhibitors of HIV integrase, another RNase H-fold
protein, inhibited the replication of viruses from all herpesvirus
genera, too (Yan et al., 2014). Based on a co-regulatory tran-
scriptional network for both RAG-1 and RAG-2, and the genes
for herpesviral DNA-binding proteins, and based on signature
sequence homologies between V(D)J recombination sites and the
viral terminal repeats, an evolutionary relationship between the
RAG recombinase and herpesviral DNA-binding proteins was
proposed. The RAG locus may have originally been introduced
to host cells by a primordial herpesvirus (Dreyfus, 2009). We
found a striking co-linearity of structural and functional elements
between the cellular immunoglobulin gene loci and the left part
of the EBV genome. Therefore, although speculative, we agree
with the view that, in the case of the RAG genes, the appearance
of the adaptive immune system may have been dependent on a
primordial herpesvirus genome and, in the case of the B cell, may
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have developed further as consequence of an evolutionary ping-
pong game between EBV and the host cell (Niller et al., 2004).
EPIGENETIC INTERACTIONS BETWEEN EBV AND ITS HOST
CELLS
Epstein–Barr virus infects both B lymphocytes and epithelial cells
in vivo. It enters B cells after binding to CD21, a cell surface
molecule absent from epithelial cells. However, EBV-infected B
cells are capable to transfer the virus to epithelial cells lacking
the EBV receptor. Both B cells and epithelial cells can support
productive (lytic) EBV replication when all of the proteins and
non-translated RNAs encoded by the viral genome are expressed
in a sequential order. EBV also causes latent infections, typically
in resting memory B cells and in various neoplastic cells that
usually carry circular, double stranded viral genomes. During
latency, only a restricted set of EBV promoters is active. The
activity of latent EBV promoters depends on the phenotype
of host cells, and it is controlled by the epigenetic regulatory
machinery. Based on the epigenetic marks deposited on the
viral chromatin by the cellular epigenetic machinery one can
distinguish between viral epigenotypes that are associated with
unique patterns of viral gene expression (reviewed in Minarovits,
2006). In parallel, certain latent EBV proteins characteristic for
the major cell types carrying latent EBV genomes act as epigenetic
regulators themselves: they alter the cellular epigenotype and gene
expression pattern and may contribute to the development of
malignant tumors. Thus, the situation is similar to an “epigenetic
dialog,” indeed. Typical examples of EBV latency types are sum-
marized in Table 1, based on the nomenclature suggested by Klein
et al. (2013; see also Laytragoon-Lewin et al., 1995; Niller et al.,
2012).
EPIGENETIC CONTROL OF EBV LATENCY PROMOTERS
The epigenetic regulatory mechanisms of host cells not only con-
trol the preservation of cell type-specific gene expression patterns
from cell generation to cell generation, but ensure the main-
tenance of host cell-dependent usage of latent EBV promoters
as well. Epigenetic regulation is based on writing, reading, and
erasing epigenetic marks on chromatin as well as on protein–DNA
interactions that are stable even in mitotic, highly condensed
chromatin (reviewed in Gopalakrishnan et al., 2008; Zaret et al.,
2008; Sharma et al., 2010; Blomen and Boonstra, 2011). Euchro-
matic marks favor transcription whereas heterochromatic marks
are associated with a more condensed chromatin structure that
usually represses promoter activity.
DNA methylation is involved in silencing of most latent EBV
promoters. It is well documented that the alternative promot-
ers Wp and Cp, where transcripts coding for six EBNAs are
initiated can be switched off by CpG methylation. In addition,
LMP1p and LMP2Ap, the promoters for LMP1 and LMP2A
transcripts are silenced by the activity of cellular DNA methyl-
transferases, too. DNA methylation does not play a role, how-
ever, in switching off Qp, an alternative promoter for EBNA1
transcripts (reviewed in Li and Minarovits, 2003; Niller et al.,
2012). One may speculate, that EBNA2, the major transactivator
protein encoded by the EBV genome that interacts with both
histone acetyltransferases and histone deacetylases (reviewed in
Niller et al., 2009) may activate key cellular genes mediating
genome-wide demethylation in LCLs. Acetylation of histone H3
and histone H4 molecules and di- or trimethylation of lysine 4
of histone H3 (H3K4me2 or H3K4me3) are euchromatic marks
frequently associated with active Cp, Qp, LMP1p, and LMP2Ap
(reviewed in Niller et al., 2012; Arvey et al., 2013). In principle,
complexes formed by Polycomb and Trithorax group proteins
that modify histone tails could also play a role in the regulation
of latent EBV promoters but there are no data supporting such
a mechanism. In contrast, Polycomb group protein EZH2 was
observed to leave a heterochromatic histone mark (H3K27me3)
at early lytic promoters of EBV that are silent during latency,
and chromatin immunoprecipitation proved the association of
the EZH2 methyltransferase with this class of viral promoters
in the BL cell line Raji (Woellmer et al., 2012). The immediate-
early promoter Zp, where transcripts for the lytic cycle initiating
BZLF1 protein are initiated was also found to be repressed by
H3K27me3 but also by H4K20me3 in Raji cells (Murata et al.,
2012).
Pioneer transcription factors and variant histone molecules
that bind to repressive chromatin areas and mark the genes to be
activated have not been implicated in the control of EBV latency.
Chromatin loops formed by binding of insulator proteins to EBV
episomes may play a role, however, in the epigenetic regulation of
the latency promoters Cp and Qp (Tempera et al., 2011).
EBV-ENCODED ONCOPROTEINS AS EPIGENETIC
REGULATORS
The methylation patterns of NPC cells and EBVaGC cells differ
from their normal counterparts: these neoplastic cells regularly
carry hypermethylated genomic regions with silenced cellular
promoters (Iizasa et al., 2012; Lo et al., 2012). Focal hyper-
methylations frequently inactivate tumor suppressor genes and
may contribute to carcinogenesis and tumor progression. Because
the EBV-encoded transmembrane proteins LMP1 and LMP2A
are capable of upregulating the cellular DNA methyltransferases
DNMT1, DNMT3A, and DNMT3B, it was suggested that hyper-
methylation of CpG rich sequences, the so called CpG islands,
is mediated by LMP1 or LMP2A in EBV-associated carcinomas
(reviewed in Niller et al., 2012). LMP1 and LMP2A are expressed
in EBV positive Hodgkin lymphomas as well. Thus, they may
contribute to gene silencing in these neoplasms, too.
It is worthy to note that, similarly to the EBV-associated
carcinomas, LCLs established by in vitro EBV-infection of B cells
also express LMP1 and LMP2A that could potentially upregu-
late DNA methyltransferases. It was observed, however, that the
typical epigenetic change in LCLs is a widespread demethylation
of the B cell methylome affecting one third of all cellular genes
and 2.18 GB of the genome (Hansen et al., 2014). The mecha-
nism of demethylation remains to be established. Furthermore,
the EBV episomes carried by LCLs are also hypomethylated, in
contrast to the overall hypermethylation of EBV genomes in
latency type I BL lines, BL biopsies, and EBV-associated car-
cinomas (Minarovits et al., 1991; Fernandez et al., 2009). The
viral oncoproteins EBNA3A and EBNA3C expressed during in
vitro immortalization of B cells silence distinct cellular tumor
suppressor genes by depositing a heterochromatic histone mark
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via the Polycomb repressor complex PCR2 (reviewed in Allday,
2013). The dominant change in EBV immortalized B cells seems
to be, however, a genome-wide decrease and redistribution of
heterochromatic marks (Hernando et al., 2014). The EBV latency
products eliciting the reprograming of the host cell epigenome
in LCLs remain to be elucidated. Contrary to LCLs, primarily
malignant lymphomas, i.e., BL and other lymphomas, are char-
acterized not by a massive and wide-spread hypomethylation, but
by a local hypermethylation of selected genomic loci (Martin-
Subero et al., 2009a,b; Kreck et al., 2013; reviewed in Niller et al.,
2014b).
In contrast to BL tumors, in which hypermethylated loci are
strongly enriched for polycomb repressive complex (PRC) target
genes of embryonic stem cells, hypermethylated genes in EBVaGC
are not enriched for PRC targets (Martin-Subero et al., 2009a;
Matsusaka et al., 2011). Contrary to Helicobacter pylori-associated
GC, EBVaGC does not emerge from an “epigenetic field” in the
gastric mucosa (Matsusaka et al., 2011; Niller et al., 2014a). Thus,
EBV-associated epigenetic changes may quite quickly set the stage
for malignancy (Au et al., 2005; Niller et al., 2014a). Notably,
even transient EBV infection of epithelial cells leaves permanent
epigenetic scars indicating past infection (Queen et al., 2013;
Birdwell et al., 2014).
Although there are no data as to the interaction of host
cell-encoded pioneer transcription factors and the EBV genome,
certain viral proteins that bind to both viral and cellular DNA and
remain associated with mitotic chromosomes may act as pioneer
transcription factors. EBNA1, a nuclear protein expressed in all
EBV latency types is a putative pioneer factor functionally resem-
bling transcription factors of the FoxA family that act as epigenetic
regulators controlling important developmental processes (Niller
et al., 2012). EBNA1 was shown to bind to different sets of cellular
promoters in cell lines of epithelial and lymphoid origin, and
upregulation as well as downregulation of distinct gene batteries
was observed (Canaan et al., 2009). In the BL cell line Raji, EBNA1
was shown to interact with a large number of cellular genes as
well as LINE elements, and high affinity EBNA-binding sites were
observed in a repetitive sequence in chromosome 11 (Lu et al.,
2010).
BZLF1, an immediate-early EBV protein initiating produc-
tive viral replication that preferentially binds methylated DNA
sequences was also suggested to act as a pioneer transcription
factor (Woellmer et al., 2012). BZLF1 is expressed not only during
the lytic cycle but transiently also during the establishment of
latent infection of B cells in vitro (Kalla and Hammerschmidt,
2012). Because BZLF1 can bind to cellular promoters (Lan et al.,
2013) and elicit epigenetic alterations (Woellmer et al., 2012),
an “epigenetic dialog” between the latent EBV genomes and the
host cell genome may occur, indeed: transient BZLF1 expression
may change the cellular epigenotype followed by silencing of the
BZLF1 promoter through the cellular epigenetic machinery. In
parallel, EBV-encoded epigenetic regulators may leave their marks
on the cellular epigenotype in a next phase of EBV-mediated B cell
immortalization.
In conclusion, on an evolutionary time scale a genetic
exchange between herpesviruses and their hosts is evident. Begin-
ning with the early steps of viral infection, epigenetic interactions
between virus and host cell are taking place. The multi-tiered
epigenetic dialog between EBV and its host needs to be elucidated
in greater molecular detail in order to understand the diverse
outcomes of infection.
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